Dianthus Therapeutics (DNTH) Operating Expenses (2017 - 2026)

For the trailing twelve months through Sep 30, 2025, Operating Expenses at Dianthus Therapeutics was $143.39 million, up 62.4% year-over-year; for FY2024, it was $108.1 million, up 112.0% from FY2023.

• Annual Operating Expenses shows a five-year compound annual growth rate of 5.4% (FY2019 to FY2024).
• In prior years, Dianthus Therapeutics' Operating Expenses was $51 million in FY2023 (+41.2%), $36.12 million in FY2022 (-51.6%), $74.69 million in FY2021 (-5.1%) and $78.7 million in FY2020 (-5.1%).
• The Q3 2025 figure stands as the highest quarterly Operating Expenses in data going back to Q2 2017.
• On a year-over-year basis, Operating Expenses has increased in each of the last nine quarters, with growth averaging 78.4% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q4 2024, with growth of 147.8%; the weakest was Q1 2023, with a decline of 65.8%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $35.12 million (Q2 2025), $34.34 million (Q1 2025) and $33.24 million (Q4 2024).